AU Patent

AU2017315273B2 — Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same

Assigned to Zogenix International Ltd · Expires 2021-04-29 · 5y expired

What this patent protects

Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT

USPTO Abstract

Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT

Drugs covered by this patent

Patent Metadata

Patent number
AU2017315273B2
Jurisdiction
AU
Classification
—
Expires
2021-04-29
Drug substance claim
No
Drug product claim
No
Assignee
Zogenix International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.